Wesbanco Bank Inc. Sells 12,309 Shares of Bristol Myers Squibb Company $BMY

Wesbanco Bank Inc. lessened its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 5.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 232,773 shares of the biopharmaceutical company’s stock after selling 12,309 shares during the quarter. Wesbanco Bank Inc.’s holdings in Bristol Myers Squibb were worth $12,556,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in the company. waypoint wealth counsel bought a new stake in shares of Bristol Myers Squibb during the 4th quarter valued at about $1,194,000. Stephens Inc. AR boosted its position in shares of Bristol Myers Squibb by 13.5% during the 3rd quarter. Stephens Inc. AR now owns 273,343 shares of the biopharmaceutical company’s stock valued at $12,328,000 after acquiring an additional 32,476 shares during the last quarter. Phoenix Financial Ltd. boosted its position in shares of Bristol Myers Squibb by 110.1% during the 3rd quarter. Phoenix Financial Ltd. now owns 106,154 shares of the biopharmaceutical company’s stock valued at $4,789,000 after acquiring an additional 55,624 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Bristol Myers Squibb by 4.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,211,845 shares of the biopharmaceutical company’s stock valued at $99,754,000 after acquiring an additional 93,528 shares during the last quarter. Finally, Fjarde AP Fonden Fourth Swedish National Pension Fund boosted its position in shares of Bristol Myers Squibb by 7.8% during the 3rd quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 510,606 shares of the biopharmaceutical company’s stock valued at $23,028,000 after acquiring an additional 37,100 shares during the last quarter. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Performance

Shares of NYSE BMY opened at $56.10 on Friday. The stock has a market cap of $114.56 billion, a price-to-earnings ratio of 15.76, a P/E/G ratio of 0.16 and a beta of 0.26. The company has a current ratio of 1.42, a quick ratio of 1.28 and a debt-to-equity ratio of 2.10. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $62.89. The stock’s 50-day moving average is $59.28 and its 200 day moving average is $54.91.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. The company had revenue of $11.49 billion for the quarter, compared to analysts’ expectations of $10.93 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.Bristol Myers Squibb’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period last year, the firm posted $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.29 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd were paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 4.5%. The ex-dividend date of this dividend was Thursday, April 2nd. Bristol Myers Squibb’s payout ratio is 70.79%.

Analysts Set New Price Targets

BMY has been the subject of a number of research analyst reports. Leerink Partners lifted their price target on Bristol Myers Squibb from $54.00 to $60.00 and gave the company an “outperform” rating in a research report on Tuesday, January 13th. Citigroup reiterated a “neutral” rating on shares of Bristol Myers Squibb in a research report on Friday, May 1st. Wells Fargo & Company reissued an “outperform” rating and set a $60.00 price objective (up from $55.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. UBS Group reissued a “buy” rating and set a $70.00 price objective on shares of Bristol Myers Squibb in a report on Friday, March 6th. Finally, Scotiabank reissued a “sector perform” rating and set a $60.00 price objective (up from $53.00) on shares of Bristol Myers Squibb in a report on Friday, January 9th. Eight analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $61.31.

Insider Buying and Selling

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of Bristol Myers Squibb stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the transaction, the executive vice president directly owned 159,248 shares of the company’s stock, valued at $9,820,824.16. The trade was a 15.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.05% of the stock is owned by company insiders.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.